Abstract: The invention relates, inter alia, to 3,4,5-trihydroxypiperidine compounds of Formula (I), infra, to methods for the manufacture of said compounds, to pharmaceutical compositions containing said compounds and to methods for the use of said compounds and compositions. Also included in the invention are concentrates, premixes and feedstuffs containing said compounds.

Abstract: The invention relates to an antibiotic compound which can be in the iron-free or iron-containing form and has the structural formula (A) as described herein. The compound possesses antimicrobial activity. Also included in the invention are fermentation processes for preparation of the above-mentioned antibiotic compound. In addition, the invention includes pharmaceutical compositions containing said antibiotic compound and the use of said antibiotic compound and compositions for combating bacterial infections.

Abstract: The invention relates to an antibiotic compound which can be in the iron-free or iron-containing form and has the structural formula (B) as described herein. The compound posesses antimicrobial activity. Also included in the invention are fermentation processes for preparation of the above-mentioned antibiotic compound. In addition, the invention includes pharmaceutical compositions containing said antibiotic compound and the use of said antibiotic compound and compositions for combating bacterial infection.

Abstract: A process for the production of a storage-stable preparation of micro-organisms, starting from a mixed culture of micro-organisms, which is capable to degrade products of industrial organic syntheses, which comprises that the culture conditions of an active mixed culture enriched in the customary manner are optimized, with the addition of the product to be degraded, in the customary manner according to the rate of degradation of the product and this mixed culture is converted in at least two passes into a stabilized activated mixed culture under the optimum conditions thus determined, and the culture thereby obtained is rendered storage-stable, its activity being maintained.

Abstract: According to the present invention inhibitors for glycoside hydrolases, and in particular glucosidase inhibitors especially saccharase inhibitors, which are active in the digestive tract are formed by culturing organisms of the family Bacillaceae, particularly by strains of the genus Bacillus.It has also been found that certain strains of organisms of the family Bacillaceae, especially strains DSM 7, DSM 704 and DSM 675 produce the antibiotic known as 1-desoxynojirimycin. The invention therefore provides a method of producing 1-desoxynojirimycin which comprises culturing a 1-desoxynojirimycin producing organism of the genus Bacillus. Inhibitors for glycoside hydrolases and the invention includes methods for producing such inhibitors, pharmaceutical compositions containing the inhibitors and methods of treatment involving the use of the inhibitors.

Abstract: The invention relates to a novel process for the production of 1-desoxynojirimycin which involves culturing an organism of the Bacillaceae family in a nutrient solution as a temperature of about 15.degree. to 80.degree. C. in a fermentation vessel, whilst aerating and then isolating the 1-desoxynojirimycin, said nutrient solution containing sorbitol as the source of carbon.

Abstract: A herbicidally active compound of the empirical formula C.sub.10 H.sub.14 N.sub.6 O.sub.3, exhibiting substantially the IR KBr-absorption spectrum shown in FIG. 2, is produced by aerobic culturing of a micro-organism of the family of the Actinoplanaceae under aerobic conditions in a nutrient medium which contains an assimilable carbon source, at least one assimilable nitrogen source and mineral salts, at a pH of 6 to 8 and a temperature of 20.degree. to 40.degree. C.

Abstract: The invention relates to a process for isolating O-{4,6-dideoxy-4-[[1S-(1,4,6/5)-4,5,6-trihydroxy-3-hydroxymethyl-2-cyclohe xen-1-yl]-amino]-.alpha.-D-glucopyranosyl}-(1.fwdarw.4)-O-.alpha.-D-glucopy ranosyl-(1.fwdarw.4)-D-glucopyranose from culture broths such as are obtained by fermenting micro-organisms of the family Actinoplanaceae, especially of strains of the genus Actinoplanes involving the use of ion exchangers.

Abstract: New amino sugars which are glucopyranosyl and oligoglucosidyl derivatives of 4,6-bisdesoxy-4-(4,5,6-trihydroxy-3-hydroxymethylcyclohex-2-en-1-ylamin o)-.alpha.-D-glucopyranose inhibit glycoside hydrolases of the digestive tract. The compounds, of which O-{4,6-bisdesoxy-4-[1S-(1,4,6/5)-4,5,6-trihydroxy-3-hydroxymethylcyclohex- 2-en-1-ylamino]-.alpha.-D-glucopyranosyl}-(1.fwdarw.4)-O-.alpha.-D-glucopyr anosyl-(1.fwdarw.4)-D-glucopyranose is a representative embodiment, demonstrate both saccharase and amylase inhibiting properties.

Abstract: Strains of Actinoplanes produce an antibiotic substance upon aerobic cultivation. The antibiotic is soluble in water with a pronounced band in the UV absorption spectrum at 267 nm. Methods for preparing and using the antibiotic, both therapeutically and for promoting livestock growth, and composition adapted for these uses are described.

Abstract: Strains of Actinoplanes produce an antibiotic substance upon aerobic cultivation. The antibiotic is sparingly soluble in water with a pronounced band in the UV absorption spectrum at 307 nm. Methods for preparing and using the antibiotic, both therapeutically and for promoting livestock growth, and composition adapted for these uses are described.

Abstract: The invention relates to a saccharase inhibitor derived from Actinoplanaceae Strain CBS 961.70, including mutants and variants thereof, means for the production of said saccharase inhibitors comprising cultivation of Actinoplanaceae Strain CBS 961.70, including mutants and variants thereof, in appropriate nutrient solutions which are characterized by being starch free under conditions most favorable to growth and production of said saccharase inhibitor and recovering a saccharase inhibitor from culture broths of said nutrient solutions, as well as the use of said inhibitor in pharmaceutically acceptable therapeutic compositions suitable for use in the treatment and relief of conditions indicative of adiposity, diabetes, pre-diabetes, hyperlipaemia (atherosclerosis), caries and the like.

Abstract: This invention relates to inhibitors for glycosidehydrolases derived from bacteria of the order Actinomycetales, means for their production comprising cultivation of a microorganism of the order Actinomycetales in appropriate nutrient solutions under conditions most favorable to growth and production of the enzyme inhibitor and recovering, as a new product, glycoside-hydrolase enzyme inhibitors, from the culture as well as the use of said enzyme inhibitors in pharmaceutically acceptable therapeutic compositions in the treatment of conditions indicating obesity, diabetes, pre-diabetes, gastritis, gastric ulcer, hyperlipidemia (arteriosclerosis) and the like.

Abstract: The invention relates to an amylase inhibitor for glycoside-hydrolases derived from a new strain of microorganism, mutants and variants thereof, of the order Actinomycetales, means for their production comprising cultivation of the new strain of the order Actinomycetales, mutants and variants thereof, in appropriate nutrient solutions under conditions most favorable to growth and production of said amylase inhibitor and recovering an amylase inhibitor from culture broths of said nutrient solutions and said new strain of microorganism, mutants and variants thereof, of the order Actinomycetales as well as the use of said enzyme inhibitor in pharmaceutically acceptable therapeutic compositions suitable for use in the treatment and relief of conditions indicative of obesity, diabetes, pre-diabetes, gastritis, gastric and duodenal ulcers, hyperlippidemia (atheriosclerosis) and the like.

Abstract: This invention relates to inhibitors for glycoside-hydrolases derived from bacteria of the order Actinomycetales, means for their production comprising cultivation of a microorganism of the order Actinomycetales in appropriate nutrient solutions under conditions most favorable to growth and production of the enzyme inhibitor and recovering, as a new product, glycoside-hydrolase enzyme inhibitors, from the culture as well as the use of said enzyme inhibitors in pharmaceutically acceptable therapeutic compositions in the treatment of conditions indicating obesity, diabetes, pre-diabetes, gastritis, gastric ulcer, hyperlipidemia (arteriosclerosis) and the like.

Abstract: An inhibitor for .alpha.-amylases, particularly pancreas amylase, is extracted from wheat, as for example, wheat flour or wheat gluten, by means of aqueous alcoholic solutions of lower alcohols of 1 to 3 carbon atoms, or dilute aqueous acid solutions having a pH of from 1 to 5, or of mixtures of the aqueous alcoholic solutions with dilute acids, and separating the desired amylase inhibitor contained in the aqueous phase from the extraction mixture by known methods. The amylase inhibitor thus obtained is particularly effective against pancreas amylase and is indicated as a therapeutic agent for the treatment of conditions resulting from alimentary hyperglycemia, such as adiposity, arteriosclerosis, diabetes and prediabetes.

Abstract: The invention relates to a saccharase inhibitor derived from Actinoplanaceae Strain CBS 961.70, including mutants and variants thereof, means for the production of said saccharase inhibitors comprising cultivation of Actinoplanaceae Strain CBS 961.70, including mutants and variants thereof, in appropriate nutrient solutions which are characterized by being starch free under conditions most favorable to growth and production of said saccharase inhibitor and recovering a saccharase inhibitor from culture broths of said nutrient solutions, as well as the use of said inhibitor in pharmaceutically acceptable therapeutic compositions suitable for use in the treatment and relief of conditions indicative of adiposity, diabetes, pre-diabetes, hyperlipaemia (atherosclerosis), caries and the like.

Abstract: This invention relates to the production of saccharase inhibitors in which a polysaccharidic or oligosaccharidic amylase inhibitor is hydrolytically degraded either enzymatically or by acid hydrolysis. The invention also relates to the use of said saccharase inhibitors in pharmaceutically acceptable therapeutic compositions in the treatment of conditions indicating adiposity, hyperlipaemia (atherosclerosis), diabetes, pre-diabetes, caries and the like.